Mark J. Ratain to Doxorubicin
This is a "connection" page, showing publications Mark J. Ratain has written about Doxorubicin.
Connection Strength
0.633
-
A phase I study of liposomal doxorubicin (Doxil) with topotecan. Am J Clin Oncol. 2000 Jun; 23(3):297-300.
Score: 0.164
-
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol. 1997 Aug; 8(8):807-9.
Score: 0.135
-
Phase I study of escalating does of carboplatin. Cancer Chemother Pharmacol. 1994; 34(6):535-6.
Score: 0.105
-
Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol. 1991 May; 9(5):871-6.
Score: 0.087
-
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007 Feb 15; 13(4):1246-52.
Score: 0.065
-
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. Ann Oncol. 2001 Dec; 12(12):1743-7.
Score: 0.045
-
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther. 1989 Apr; 45(4):340-7.
Score: 0.019
-
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704.
Score: 0.007
-
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report. Gynecol Oncol. 1989 Dec; 35(3):391-4.
Score: 0.005